Life science focussed Intuitive Investments Group plc AIM IPO raises £7.85 million

Per Matsson to act as Nordic advisor for fund targeting high potential diagnostics and healthcare, medical devices, tools and technologies, bio-therapeutics and pharmaceuticals  

London, December 15, 2020, Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announced that it has raised £7.85 million (before expenses) in its AIM float by placing 39,250,000 new Ordinary Shares at 20p. The net proceeds of the Placing will be used by the Company to invest in fast growing and / or high potential Life Sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities. Investments will be focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals. The Company also has a strong interest in the Nordics through several members of the management and advisory panel.

Intuitive has both a strong management team and advisory panel. David Evans will serve as executive chairman. He has over 27 years of experience in the Life Science sector, both in private companies and as a senior director of a number of public companies. David has facilitated 12 companies’ transition to being publicly traded (directly or indirectly), has overseen four successful exits and has extensive experience chairing numerous UK public companies’ boards. He has been actively engaged in a number of M&A transactions and has a record of high returns from personal investments in the Life Science sector. The Advisory Panel is chaired by Dr. Stewart White, who) has acted as Chairman and CEO of numerous Life Science companies. Stewart is a visiting professor at the University of Glasgow and has a PhD in Bioprocessing. He is joined by:

Julian Baines is CEO of EKF Diagnostics Holdings plc (AIM:EKF) and holds an MBE for services in the Life Science sector.

Ron Long has held a number of positions as CEO and Chairman of Life Science companies and several start-up businesses.

Per Matsson has experience in senior positions in various Life Science R&D departments. He is also an associate professor in Veterinary Science and holds a PhD in biology.

Alastair Smith, CEO of Avacta Group plc (AIM:AVCT), was previously a professor of Molecular Biophysics and has a PhD in Physics.

David Evans, Executive Chairman of IIG, commented:

“We are very pleased to be joining the AIM market today. With our combined experience and demonstrative track record in the sector, we will look to the future and invest in fast growing and / or high potential life sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities.

“We will seek investments focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals. IIG’s proposition is based on my belief that through the skillful deployment of capital, we can advance the growth of companies with greater certainty than otherwise might be the case and provide a superior return to other alternative investment opportunities for investors.”

The Company’s Admission Document is available here: www.iigplc.com

For further information, please contact:

Important Information

This announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment therefor. 

The information contained in this announcement is for background purposes only and does not purport to be full or complete.. No reliance may or should be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The information in this announcement is subject to change.